AstraZeneca Reports Results of Capivasertib in P-III Trial for the Treatment of Advanced HR-positive Breast Cancer
Shots:
- The P-III (CAPItello-291) trial evaluates the safety & efficacy of capivasertib + Faslodex vs PBO + Faslodex in patients (n=708) with locally advanced or metastatic HR-positive, HER2-low or negative breast cancer
- The results depicted an improved PFS in overall patients & in the prespecified biomarker subgroup of patients whose tumors had alterations in the PIK3CA, AKT1, or PTEN genes vs PBO + Faslodex whereas the OS analysis showed positive early data which will further be analyzed in the trial as 2EPs
- Capivasertib is a selective ATP-competitive inhibitor of all three AKT isoforms (AKT1/2/3) being evaluated in combination with existing therapies in tumors with alterations in the PI3K/AKT/PTEN pathway & in tumors reliant on signaling through this pathway
Ref: Businesswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
